AtaGenix Laboratories
AtaGenix Laboratories
Release time: 2026-09-28 View volume: 8
An antibody that binds its target with high affinity can still fail as a therapeutic if it aggregates, expresses poorly, or has unfavorable pharmacokinetics. Developability assessment evaluates these manufacturing and clinical risk factors early — ideally before lead selection — to prioritize candidates that will perform well throughout development. This guide covers the key assays, decision criteria, and how developability data integrates into antibody lead selection.
Developability refers to the collection of biophysical, biochemical, and pharmacological properties that determine whether an antibody can be manufactured consistently, formulated at clinical concentrations, and dosed safely. These properties are largely intrinsic to the antibody sequence and structure — they are difficult or impossible to fix later without altering the variable regions, which risks changing binding specificity. Assessing developability at the lead selection stage allows programs to deselect problematic candidates before investing 12–18 months in cell line development, process optimization, and preclinical studies that would be wasted if the molecule ultimately cannot be manufactured or formulated.
| Property | Assay(s) | Risk Threshold |
|---|---|---|
| Thermal stability | DSF (Tm, Tonset), DSC | Tm1 <60°C or Tonset <55°C is a flag |
| Aggregation propensity | SEC (%HMW), DLS (polydispersity), accelerated stability (40°C, 2–4 weeks) | >2% HMW at baseline or >5% after 4 weeks at 40°C |
| Self-interaction | AC-SINS (affinity capture self-interaction nanoparticle spectroscopy), CIC (cross-interaction chromatography) | High AC-SINS Δλmax (>10 nm) or CIC retention time shift indicates self-association |
| Non-specific binding (polyreactivity) | BVP ELISA (baculovirus particle), PSR (polyspecificity reagent), HEK cell binding | High polyreactivity scores correlate with fast in vivo clearance and off-target toxicity |
| Expression yield | Transient expression titer (HEK293 or CHO) | <50 mg/L transient titer may indicate expression or folding problems |
| Chemical stability | Asp isomerization, Asn deamidation, Met oxidation (LC-MS peptide mapping) | Labile sites in CDRs (especially CDR-H3) are high-risk for potency loss over shelf life |
| Viscosity | Microfluidic viscometer or cone-and-plate at ≥100 mg/mL | >20 cP at target concentration impairs subcutaneous injectability |
Antibodies with high non-specific binding to cell-surface components, extracellular matrix, or intracellular proteins (polyreactivity) are cleared faster in vivo because they are taken up non-specifically by tissues and routed to lysosomal degradation. This manifests as unexpectedly short half-life despite normal FcRn binding — a phenomenon termed “target-independent clearance.” Highly polyreactive antibodies may also show off-target tissue binding in immunohistochemistry panels, raising toxicology concerns. Screening for polyreactivity at the lead selection stage using BVP ELISA or PSR flow cytometry is a cost-effective way to avoid candidates that will fail in pharmacokinetic studies.
Computational tools can flag potential developability liabilities directly from the antibody sequence, before any protein is produced. Key analyses include spatial aggregation propensity (SAP) mapping of the variable domain surface, identification of chemical degradation motifs in CDRs (NG, DG, DS, NS deamidation/isomerization sites; unpaired cysteines; surface-exposed Met/Trp oxidation sites), T-cell epitope prediction for immunogenicity risk assessment, and net charge and charge distribution analysis (highly positive patches correlate with polyreactivity and fast clearance). In silico assessment is best used as a first-pass filter: candidates with multiple high-risk flags can be deprioritized before committing to protein expression, reserving experimental developability testing for the strongest leads.
A practical lead-selection framework:
• Tier 1 (must pass): Binding affinity meets target profile (SPR KD), functional activity confirmed, species cross-reactivity verified.
• Tier 2 (developability screen): Thermal stability (Tm >65°C), SEC purity (>95% monomer), no significant self-interaction (AC-SINS), low polyreactivity (BVP/PSR), expression yield (>100 mg/L transient), no CDR chemical liabilities. Candidates passing all Tier 2 criteria advance.
• Tier 3 (risk-tolerated): Candidates with one or two marginal flags (e.g., Tm 58–65°C, moderate self-interaction) may advance if they offer unique epitope or mechanism-of-action differentiation, with the understanding that formulation development may be challenging.
• Deselect: Candidates with multiple flags across different property categories should be deselected regardless of binding potency. The best KD in the world does not help if the molecule cannot be manufactured at clinical scale.
Some properties can be improved: viscosity can often be addressed through formulation optimization (arginine, NaCl); chemical degradation hotspots can sometimes be mutated without affecting binding; and expression yield can be improved through codon optimization, signal peptide engineering, or host cell engineering. However, fundamental problems like high aggregation propensity, strong self-interaction, or extensive polyreactivity are typically intrinsic to the variable domain topology and resist downstream fixes. This is why assessing these properties before lead selection — when alternative candidates are still available — is far more efficient than trying to engineer around them later.
Need developability assessment for your antibody candidates? AtaGenix offers comprehensive biophysical characterization and developability screening integrated into antibody discovery and lead optimization workflows.
Talk to Technical SupportResponse within 24 hours
Contact Us
+86-27-65523339
info@atagenix.com
Building C, R & D Building, No. 666, Shendun 4th Road, Donghu New Technology Development Zone, Wuhan
